Scarica l'app Stockscreener
106.13
3.95%
4.03
Dopo l'orario di chiusura:
106.13
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
RYTM Initiated Coverage by JP Morgan -- Rating Overweight with $145 PT - GuruFocus
RHYTHM PHARMACEUTICALS INC : JP MORGAN INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET $145 - Bitget
Rhythm Pharmaceuticals Inc - TradingKey
JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals (RYTM) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. Revenue Breakdown – FWB:1RV - TradingView
Rhythm Pharmaceuticals (RYTM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Earnings Dates, Call Summary & Reports - TipRanks
Rhythm Pharmaceuticals Inc (RYTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth - Ad-hoc-news.de
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - The Manila Times
Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM - TradingView
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - Sahm
Rhythm Pharmaceuticals (RYTM) Edges Higher, Nears Key Resistance LevelSymmetrical Triangle - dars.gov.et
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Travere Therapeutics (TVTX) - The Globe and Mail
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine. - Bitget
Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces The New England Journal of - GlobeNewswire
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - Yahoo Finance UK
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151 - Moomoo
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - Ad-hoc-news.de
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
RYTMRhythm Pharmaceuticals Inc Options - Finviz
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
Rhythm Pharmaceuticals stock trades up to $111.03 as Rhythm Pharmaceuticals closes offices for July 4th break - Traders Union
Rhythm Pharmaceuticals Stock Surges 28%, With A 12-Day Winning Spree - Trefis
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Insider Monkey
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):